Phase II trial of pirarubicin in the treatment of advanced bladder cancer |
| |
Authors: | M. Mahjoubi J. Kattan M. Ghosn J. -P. Droz I. Philippot P. Herait |
| |
Affiliation: | (1) Department of Medicine, Institut Gustave-Roussy, 94800 Villejuif, France |
| |
Abstract: | Summary Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclinical studies. Twenty one patients with either metastatic or inoperable locally advanced bladder carcinoma were treated with intravenous infusion of pirarubicin: 25 mg/m2/day for 3 days every 4 weeks in the first 15 patients and 20 mg/m2/day for 3 days every 3 weeks in the others. Fifteen patients were not pretreated and 6 received prior chemotherapy (5 patients with doxorubicin containing regimen). Twenty patients were evaluable for response; there were 2 partial response, 8 stable disease and 10 progressive disease. All pretreated patients progressed. Hematological toxicity was moderate, however there was one toxic death with grade 4 neutropenia which occured in a heavily pretreated patient receiving a dose of 25 mg/m2/day for 3 days. There was no clinical cardiac toxicity. Single agent Pirarubicin displays an objective response rate of 10% (95% of CI 0 to 23%) which reaches 14% (95% CI 0 to 29%) when non pretreated patients are analyzed separately. This rate is in the range of doxorubicin activity. |
| |
Keywords: | bladder cancer advanced stage pirarubicin phase II trial |
本文献已被 SpringerLink 等数据库收录! |